Evidence map›Paper›PMID 25897591›Full record

ArticleACS chemical biology2015

Formation of a Novel Macrocyclic Alkaloid from the Unnatural Farnesyl Diphosphate Analogue Anilinogeranyl Diphosphate by 5-Epi-Aristolochene Synthase.

Kathleen A Rising, Charisse M Crenshaw, Hyun Jo Koo, Thangaiah Subramanian, Kareem A H Chehade, Courtney Starks, Keith D Allen, Douglas A Andres, H Peter Spielmann, Joseph P Noel and 1 more

Abstract read
In one paragraph

Article in ACS chemical biology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.

0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed
1.8field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

19 citing papers in PubMed, 40 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Genome-wide detection and classification of terpene synthase genes inPhysiology and molecular biology of plants : an international journal of functional plant biology · 2021
    Article
  8. Review
  9. Review
  10. Accelerating Biphasic Biocatalysis through New Process Windows.Angewandte Chemie (International ed. in English) · 2020
    Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Review
  18. An Efficient Chemoenzymatic Synthesis of Dihydroartemisinic Aldehyde.Angewandte Chemie (International ed. in English) · 2017
    Article
  19. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 4 institutions in 1 country.

Kathleen A Rising†Departments of Pharmaceutical Sciences, ‡Cellular and Molecular Biochemistry, §Chemistry, ⊥Center for Structural Biology, ∥Markey Cancer Center, University of Kentucky, Lexington, Lexington, Kentucky, United States.
Charisse M Crenshaw†Departments of Pharmaceutical Sciences, ‡Cellular and Molecular Biochemistry, §Chemistry, ⊥Center for Structural Biology, ∥Markey Cancer Center, University of Kentucky, Lexington, Lexington, Kentucky, United States.
Hyun Jo Koo†Departments of Pharmaceutical Sciences, ‡Cellular and Molecular Biochemistry, §Chemistry, ⊥Center for Structural Biology, ∥Markey Cancer Center, University of Kentucky, Lexington, Lexington, Kentucky, United States.
Thangaiah Subramanian†Departments of Pharmaceutical Sciences, ‡Cellular and Molecular Biochemistry, §Chemistry, ⊥Center for Structural Biology, ∥Markey Cancer Center, University of Kentucky, Lexington, Lexington, Kentucky, United States.
Kareem A H Chehade†Departments of Pharmaceutical Sciences, ‡Cellular and Molecular Biochemistry, §Chemistry, ⊥Center for Structural Biology, ∥Markey Cancer Center, University of Kentucky, Lexington, Lexington, Kentucky, United States.
Courtney Starks†Departments of Pharmaceutical Sciences, ‡Cellular and Molecular Biochemistry, §Chemistry, ⊥Center for Structural Biology, ∥Markey Cancer Center, University of Kentucky, Lexington, Lexington, Kentucky, United States.
Keith D Allen†Departments of Pharmaceutical Sciences, ‡Cellular and Molecular Biochemistry, §Chemistry, ⊥Center for Structural Biology, ∥Markey Cancer Center, University of Kentucky, Lexington, Lexington, Kentucky, United States.
Douglas A Andres†Departments of Pharmaceutical Sciences, ‡Cellular and Molecular Biochemistry, §Chemistry, ⊥Center for Structural Biology, ∥Markey Cancer Center, University of Kentucky, Lexington, Lexington, Kentucky, United States.
H Peter Spielmann†Departments of Pharmaceutical Sciences, ‡Cellular and Molecular Biochemistry, §Chemistry, ⊥Center for Structural Biology, ∥Markey Cancer Center, University of Kentucky, Lexington, Lexington, Kentucky, United States.
Joseph P Noel†Departments of Pharmaceutical Sciences, ‡Cellular and Molecular Biochemistry, §Chemistry, ⊥Center for Structural Biology, ∥Markey Cancer Center, University of Kentucky, Lexington, Lexington, Kentucky, United States.
Joe Chappell†Departments of Pharmaceutical Sciences, ‡Cellular and Molecular Biochemistry, §Chemistry, ⊥Center for Structural Biology, ∥Markey Cancer Center, University of Kentucky, Lexington, Lexington, Kentucky, United States.
Howard Hughes Medical Institute · USSalk Institute for Biological Studies · USUniversity of Kentucky · USMarkey Cancer Center · US

Funding

Salk Institute Cancer Training GrantT32CA009370 · NCI · SALK INSTITUTE FOR BIOLOGICAL STUDIES · PI Diana Clare Hargreaves, Jan Karlseder · 1986 to 2026
$8.6M
Advancing Drug Development from Medicinal Plants using Transcriptomics and MetaboRC2GM092521 · NIGMS · UNIVERSITY OF KENTUCKY · PI CHAPPELL, JOE, DELLAPENNA, DEAN · 2009 to 2010
$6.0M
Synthetic Probes of Protein PrenylationR01GM066152 · NIGMS · UNIVERSITY OF KENTUCKY · PI SPIELMANN, H PETER · 2002 to 2011
$2.5M
TERPENE CYCLASES: FUNCTIONAL DOMAINS AND STRUCTURESR01GM054029 · NIGMS · SALK INSTITUTE FOR BIOLOGICAL STUDIES · PI NOEL, JOSEPH P · 1996 to 2003
$1.2M
Howard Hughes Medical InstituteNCI NIH HHS T32 CA009370NIGMS NIH HHS 1RC2GM092521NIGMS NIH HHS GM054029NIGMS NIH HHS GM66152NIGMS NIH HHS R01 GM054029NIGMS NIH HHS R01 GM066152NIGMS NIH HHS RC2 GM092521
6 · The paper itself

Abstract

As part of an effort to identify substrate analogs suitable for helping to resolve structural features important for terpene synthases, the inhibition of 5-epi-aristolochene biosynthesis from farnesyl diphosphate (FPP) by the tobacco 5-epi-aristolochene synthase incubated with anilinogeranyl diphosphate (AGPP) was examined. The apparent noncompetitive nature of the inhibition supported further assessment of how AGPP might be bound to crystallographic forms of the enzyme. Surprisingly, the bound form of the inhibitor appeared to have undergone a cyclization event consistent with the native mechanism associated with FPP catalysis. Biocatalytic formation of a novel 13-membered macrocyclic paracyclophane alkaloid was confirmed by high-resolution GC-MS and NMR analysis. This work provides insights into new biosynthetic means for generating novel, functionally diversified, medium-sized terpene alkaloids.

Indexed as

AlkaloidsAlkyl and Aryl TransferasesMacrocyclic CompoundsModels, MolecularNicotianaPolyisoprenyl PhosphatesSesquiterpenesTerpenes5-epi-aristolochene synthaseAlkaloidsAlkyl and Aryl Transferasesfarnesyl pyrophosphateMacrocyclic CompoundsPolyisoprenyl PhosphatesSesquiterpenesTerpenes

Identifiers

PMID25897591
PMCPMC4570970
OpenAlexW2064825513

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.